Population Pharmacokinetics of Delamanid and its Main Metabolite DM-6705 in Drug-Resistant Tuberculosis Patients Receiving Delamanid Alone or Coadministered with Bedaquiline

BACKGROUND AND OBJECTIVE: Delamanid is a nitroimidazole, a novel class of drug for treating tuberculosis, and is primarily metabolized by albumin into the metabolite DM-6705. The aims of this analysis were to develop a population pharmacokinetic (PK) model to characterize the concentration-time cour...

Descripción completa

Detalles Bibliográficos
Autores principales: Tanneau, Lénaïg, Karlsson, Mats O., Diacon, Andreas H., Shenje, Justin, De Los Rios, Jorge, Wiesner, Lubbe, Upton, Caryn M., Dooley, Kelly E., Maartens, Gary, Svensson, Elin M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer International Publishing 2022
Materias:
Original Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9349160/
https://www.ncbi.nlm.nih.gov/pubmed/35668346
http://dx.doi.org/10.1007/s40262-022-01133-2

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9349160/
https://www.ncbi.nlm.nih.gov/pubmed/35668346
http://dx.doi.org/10.1007/s40262-022-01133-2

Ejemplares similares